Cargando…
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979808/ https://www.ncbi.nlm.nih.gov/pubmed/34974526 http://dx.doi.org/10.1038/s41375-021-01485-x |
| _version_ | 1784681257993502720 |
|---|---|
| author | Sharman, Jeff P. Egyed, Miklos Jurczak, Wojciech Skarbnik, Alan Pagel, John M. Flinn, Ian W. Kamdar, Manali Munir, Talha Walewska, Renata Corbett, Gillian Fogliatto, Laura Maria Herishanu, Yair Banerji, Versha Coutre, Steven Follows, George Walker, Patricia Karlsson, Karin Ghia, Paolo Janssens, Ann Cymbalista, Florence Woyach, Jennifer A. Ferrant, Emmanuelle Wierda, William G. Munugalavadla, Veerendra Yu, Ting Wang, Min Hui Byrd, John C. |
| author_facet | Sharman, Jeff P. Egyed, Miklos Jurczak, Wojciech Skarbnik, Alan Pagel, John M. Flinn, Ian W. Kamdar, Manali Munir, Talha Walewska, Renata Corbett, Gillian Fogliatto, Laura Maria Herishanu, Yair Banerji, Versha Coutre, Steven Follows, George Walker, Patricia Karlsson, Karin Ghia, Paolo Janssens, Ann Cymbalista, Florence Woyach, Jennifer A. Ferrant, Emmanuelle Wierda, William G. Munugalavadla, Veerendra Yu, Ting Wang, Min Hui Byrd, John C. |
| author_sort | Sharman, Jeff P. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8979808 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89798082022-04-20 Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia Sharman, Jeff P. Egyed, Miklos Jurczak, Wojciech Skarbnik, Alan Pagel, John M. Flinn, Ian W. Kamdar, Manali Munir, Talha Walewska, Renata Corbett, Gillian Fogliatto, Laura Maria Herishanu, Yair Banerji, Versha Coutre, Steven Follows, George Walker, Patricia Karlsson, Karin Ghia, Paolo Janssens, Ann Cymbalista, Florence Woyach, Jennifer A. Ferrant, Emmanuelle Wierda, William G. Munugalavadla, Veerendra Yu, Ting Wang, Min Hui Byrd, John C. Leukemia Letter Nature Publishing Group UK 2022-01-01 2022 /pmc/articles/PMC8979808/ /pubmed/34974526 http://dx.doi.org/10.1038/s41375-021-01485-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Sharman, Jeff P. Egyed, Miklos Jurczak, Wojciech Skarbnik, Alan Pagel, John M. Flinn, Ian W. Kamdar, Manali Munir, Talha Walewska, Renata Corbett, Gillian Fogliatto, Laura Maria Herishanu, Yair Banerji, Versha Coutre, Steven Follows, George Walker, Patricia Karlsson, Karin Ghia, Paolo Janssens, Ann Cymbalista, Florence Woyach, Jennifer A. Ferrant, Emmanuelle Wierda, William G. Munugalavadla, Veerendra Yu, Ting Wang, Min Hui Byrd, John C. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia |
| title | Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia |
| title_full | Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia |
| title_fullStr | Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia |
| title_full_unstemmed | Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia |
| title_short | Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia |
| title_sort | efficacy and safety in a 4-year follow-up of the elevate-tn study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979808/ https://www.ncbi.nlm.nih.gov/pubmed/34974526 http://dx.doi.org/10.1038/s41375-021-01485-x |
| work_keys_str_mv | AT sharmanjeffp efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT egyedmiklos efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT jurczakwojciech efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT skarbnikalan efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT pageljohnm efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT flinnianw efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT kamdarmanali efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT munirtalha efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT walewskarenata efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT corbettgillian efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT fogliattolauramaria efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT herishanuyair efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT banerjiversha efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT coutresteven efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT followsgeorge efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT walkerpatricia efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT karlssonkarin efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT ghiapaolo efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT janssensann efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT cymbalistaflorence efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT woyachjennifera efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT ferrantemmanuelle efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT wierdawilliamg efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT munugalavadlaveerendra efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT yuting efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT wangminhui efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia AT byrdjohnc efficacyandsafetyina4yearfollowupoftheelevatetnstudycomparingacalabrutinibwithorwithoutobinutuzumabversusobinutuzumabpluschlorambucilintreatmentnaivechroniclymphocyticleukemia |